First narrow-spectrum antibiotic successfully eliminates Fusobacterium nucleatum

In a recent study conducted at the ADA Forsyth Institute, researchers used a specific type of agent to remove Fusobacterium nucleatum from the mouths of patients with periodontitis without disturbing the natural oral bacteria. They suggested that this type of agent could be the future of antibiotic therapy for this condition.

In their full paper, the authors also pointed out the various benefits of using such narrow-spectrum agents, as they help maintain the normal oral microbiome. Furthermore, they proposed the idea of developing antibiotics that target the modified tRNA found only in Fusobacterium nucleatum.

Trana Discovery is currently focused on researching these essential tRNA and has multiple antibiotic drug discovery programs in place.